Kezar Life Sciences, Inc. (KZR)
Chart Events
Performance Outlook
| Previous Close | 7.10 |
| Open | 7.08 |
| Bid | 6.95 x 800 |
| Ask | 6.97 x 1400 |
| Day's Range | 6.85 - 7.08 |
| 52 Week Range | 4.31 - 18.55 |
| Volume | |
| Avg. Volume | 655,708 |
| Market Cap | 475.39M |
| Beta (5Y Monthly) | 0.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.95 |
| Earnings Date | Mar 15, 2023 - Mar 20, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.75 |
- Simply Wall St.
A Kezar Life Sciences, Inc. (NASDAQ:KZR) insider increased their holdings by 9.9% last year
Insiders were net buyers of Kezar Life Sciences, Inc.'s ( NASDAQ:KZR ) stock during the past year. That is, insiders...
- Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., January 13, 2023--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase 65,000 shares of its common stock with an exercise price of $6.84 per share, which is equal to the closing price of Kezar’s common
- Business Wire
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., January 04, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John Fowler, Co-founder and Chief Executive Officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 pm PT in San Francisco, CA.
